Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 4

Participants achieving ≥50% response in participants aged ≥60 years and overall population. OR, odds ratio; CI, confidence interval. A ≥ 50% response was defined as a ≥ 50% reduction from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment. aP < 0.05 vs placebo. bP < 0.0001 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us